The United States Supreme Court has again declined to restrict mail-order access to mifepristone, the drug used in the majority of American abortions, issuing an emergency order that blocks a lower-court ruling from taking effect while a Louisiana-led lawsuit against the Food and Drug Administration winds through the judiciary. The order, issued late on Thursday, means that women in states with total abortion bans will continue to receive the medication via telehealth — a practice that, viewed from Washington, has become the central battleground in the post-Dobbs landscape.

Justice Samuel Alito, writing in dissent alongside Justice Clarence Thomas, denounced the decision as a deliberate “scheme” to circumvent the court’s 2022 ruling in Dobbs v. Jackson, which eliminated the constitutional right to abortion. Alito lamented that abortions have actually increased since Dobbs, driven overwhelmingly by telemedicine prescriptions. Data compiled by researchers and cited in the dissent show that in 2025, far more residents of states with total bans obtained medication abortion by mail than travelled to less restrictive states for in-person care. Roughly two-thirds of all abortions in the United States now involve medication, a shift that makes the availability of mifepristone a proxy war for the broader right.

The case originated in Louisiana, where state officials in October 2024 sued the FDA to revoke the agency’s approval of remote prescribing for mifepristone. A district judge in Texas had previously suspended the drug’s federal approval in a separate challenge, but that ruling was stayed by the Supreme Court. The latest litigation reached the justices via the emergency “shadow docket” after the New Orleans-based Fifth Circuit Court of Appeals ruled on May 1 that mail-order delivery and telehealth prescriptions for mifepristone must cease. The Supreme Court’s stay, which was unaccompanied by a signed opinion, keeps the drug accessible at pharmacies and through the post while the appeal proceeds — a process likely to last until at least mid-2026.

Analysts in London note that the court’s conservative majority, which includes three justices appointed by Donald Trump, has so far shown no appetite for a direct confrontation on abortion access. Instead, the justices have opted for procedural interventions that freeze lower-court restrictions without settling the underlying legal questions. That posture leaves the issue alive and, as Justice Alito’s dissent made clear, ripe for a future showdown. The next phase of the fight will almost certainly return to the high court on the merits, forcing the justices to decide whether the FDA’s regulation of medication abortion comports with the post-Dobbs legal order — a question that could redefine reproductive rights in America for a generation.